First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
Open Access
- 18 March 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (3) , e001998
Abstract
Background: CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microenvironment sometimes caused by the tumorous expression of immune checkpoints (ICPs) such as HLA-G. Indeed, HLA-G is remarkable because it is both a potent ICP and a TSA. HLA-G tumor expression causes immune escape by impairing innate and adaptive immune responses and by inducing a suppressive microenvironment. Yet, to date, no immunotherapy targets it. Methods: We have developed two anti-HLA-G third-generation CARs based on new anti-HLA-G monoclonal antibodies. Results: Anti-HLA-G CAR-T cells were specific for immunosuppressive HLA-G isoforms. HLA-G-activated CAR-T cells polarized toward T helper 1, and became cytotoxic against HLA-G+ tumor cells. In vivo, anti-HLA-G CAR-T cells were able to control and eliminate HLA-G+ tumor cells. The interaction of tumor-HLA-G with interleukin (IL)T2-expressing T cells is known to result in effector T cell functional inhibition, but anti-HLA-G CAR-T cells were insensitive to this inhibition and still exerted their function even when expressing ILT2. Lastly, we show that anti-HLA-G CAR-T cells differentiated into long-term memory effector cells, and seemed not to lose function even after repeated stimulation by HLA-G-expressing tumor cells. Conclusion: We report for the first time that HLA-G, which is both a TSA and an ICP, constitutes a valid target for CAR-T cell therapy to specifically target and eliminate both tumor cells and HLA-G+ suppressive cells.Keywords
This publication has 74 references indexed in Scilit:
- HLA-dependent tumour development: a role for tumour associate macrophages?Journal of Translational Medicine, 2013
- The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targetingBritish Journal of Cancer, 2012
- HLA-G Level on Monocytoid Dendritic Cells Correlates With Regulatory T-Cell Foxp3 Expression in Liver Transplant ToleranceTransplantation, 2011
- HLA-G: from biology to clinical benefitsTrends in Immunology, 2008
- Phenotypic and functional differentiation of KG-1 into dendritic-like cellsImmunobiology, 2008
- CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptanceBlood, 2007
- Synthesis of β2‐microglobulin‐free, disulphide‐linked HLA‐G5 homodimers in human placental villous cytotrophoblast cellsImmunology, 2007
- Trogocytosis‐based generation of suppressive NK cellsThe EMBO Journal, 2007
- Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d)Proceedings of the National Academy of Sciences, 2006
- Soluble HLA-G in Human Placentas: Synthesis in Trophoblasts and Interferon-γ-Activated Macrophages But Not Placental FibroblastsHuman Immunology, 1998